Quick Dispatch:
Your tirzepatide cvot trial Effects of tirzepatide on adjudicated cardiovascular events in orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cvot trial Effects of tirzepatide on adjudicated cardiovascular events in ships.
Need Help?
Questions about tirzepatide cvot trial Effects of tirzepatide on adjudicated cardiovascular events in, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cvot trial Effects of tirzepatide on adjudicated cardiovascular events in in your area.
01200-X/asset/429e6fd1-61d1-402a-91a5-b2ec86b1b878/main.assets/gr2_lrg.jpg "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial")
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
28.97
Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)
20.86
SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized
22.77
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
26.54
Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism
21.12
01324-6/asset/4a54a807-9d4c-43b0-9cee-525570c8c25d/main.assets/gr2_lrg.jpg "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial")
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
25.05
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
28.72
